News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • 18

    Jun

    20

  • KemPharm Issues Letter to Shareholders

  • 19

    May

    20

  • KemPharm Receives Day-74 Letter for KP415 NDA

  • 12

    May

    20

  • KemPharm Reports First Quarter 2020 Financial Results

  • 06

    May

    20

  • KemPharm to Report First Quarter 2020 Financial Results

  • 04

    May

    20

  • NDA Filing for Potential New ADHD Treatment, KP415, Accepted by FDA; KemPharm Eligible to Receive $5 Million Milestone Payment from Gurnet Point Capital

  • 02

    Mar

    20

  • KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD

  • 28

    Feb

    20

  • KemPharm Reports Fourth Quarter and Full-Year 2019 Financial Results

  • 15

    Jan

    20

  • Nasdaq Grants KemPharm’s Request for Extension to Comply with the Market Value of Listed Securities Continued Listing Requirement

  • 18

    Dec

    19

  • KemPharm Announces Debt Restructuring with Deerfield and Delaware Street Capital

  • 14

    Nov

    19

  • KemPharm Reports Third Quarter 2019 Results

  • 12

    Nov

    19

  • KemPharm to Report Third Quarter 2019 Results

  • 31

    Oct

    19

  • KemPharm Reports APADAZ® Will be Available Nationally Beginning in November 2019